Antikoagulasjonsbehandling og reversering

Reversal of antithrombotic agents. (åpner nytt vindu)

Bauer KA.

Kilde‎: Am J Hematol 2012;87 Suppl 1:S119-26.

Arkiv‎: PubMed 22460529

DOI‎: 10.1002/ajh.23165

https://www.ncbi.nlm.nih.gov/pubmed/22460529 (åpner nytt vindu)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (åpner nytt vindu)

Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M

Kilde‎: J Thromb Haemost 2015;13(10):1790-8.

Arkiv‎: PubMed 26270886

DOI‎: 10.1111/jth.13117

https://www.ncbi.nlm.nih.gov/pubmed/26270886 (åpner nytt vindu)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (åpner nytt vindu)

Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ, Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S, Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators

Kilde‎: N Engl J Med 2019;380(14):1326-35.

Arkiv‎: PubMed 30730782

DOI‎: 10.1056/NEJMoa1814051

https://www.ncbi.nlm.nih.gov/pubmed/30730782 (åpner nytt vindu)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (åpner nytt vindu)

Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4 Investigators

Kilde‎: N Engl J Med 2016;375(12):1131-41.

Arkiv‎: PubMed 27573206

DOI‎: 10.1056/NEJMoa1607887

https://www.ncbi.nlm.nih.gov/pubmed/27573206 (åpner nytt vindu)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (åpner nytt vindu)

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M

Kilde‎: Circulation 2011;124(14):1573-9.

Arkiv‎: PubMed 21900088

DOI‎: 10.1161/CIRCULATIONAHA.111.029017

https://www.ncbi.nlm.nih.gov/pubmed/21900088 (åpner nytt vindu)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (åpner nytt vindu)

Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R.

Kilde‎: Lancet 2015;385(9982):2077-87.

Arkiv‎: PubMed 25728933

DOI‎: 10.1016/S0140-6736(14)61685-8

https://www.ncbi.nlm.nih.gov/pubmed/25728933 (åpner nytt vindu)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (åpner nytt vindu)

Gordon JL, Fabian TC, Lee MD, Dugdale M

Kilde‎: J Trauma Acute Care Surg 2013;75(3):475-86.

Arkiv‎: PubMed 24089118

DOI‎: 10.1097/TA.0b013e3182a07391

https://www.ncbi.nlm.nih.gov/pubmed/24089118 (åpner nytt vindu)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (åpner nytt vindu)

Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, Chan AK, James A, Moll S, Ortel TL, Van Cott EM, Ansell J.

Kilde‎: Am J Hematol 2012;87 Suppl 1:S141-5.

Arkiv‎: PubMed 22473649

DOI‎: 10.1002/ajh.23202

https://www.ncbi.nlm.nih.gov/pubmed/22473649 (åpner nytt vindu)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (åpner nytt vindu)

Levi M, Eerenberg E, Kamphuisen PW.

Kilde‎: J Thromb Haemost 2011;9(9):1705-12.

Arkiv‎: PubMed 21729240

DOI‎: 10.1111/j.1538-7836.2011.04432.x

https://www.ncbi.nlm.nih.gov/pubmed/21729240 (åpner nytt vindu)

Emergency reversal of warfarin anticoagulation. (åpner nytt vindu)

Lin Y, Callum J.

Kilde‎: CMAJ 2010;182(18):2004.

Arkiv‎: PubMed 21078740

DOI‎: 10.1503/cmaj.100983

https://www.ncbi.nlm.nih.gov/pubmed/21078740 (åpner nytt vindu)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (åpner nytt vindu)

Marlu R, Hodaj E, Paris A, Albaladejo P, Cracowski JL, Pernod G.

Kilde‎: Thromb Haemost 2012;108(2):217-24.

Arkiv‎: PubMed 22627883

DOI‎: 10.1160/TH12-03-0179

https://www.ncbi.nlm.nih.gov/pubmed/22627883 (åpner nytt vindu)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (åpner nytt vindu)

Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group.

Kilde‎: J Thromb Haemost 2008;6(4):622-31.

Arkiv‎: PubMed 18208533

DOI‎: 10.1111/j.1538-7836.2008.02904.x

https://www.ncbi.nlm.nih.gov/pubmed/18208533 (åpner nytt vindu)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (åpner nytt vindu)

Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W, Schünemann HJ, Nieuwlaat R

Kilde‎: Blood Adv 2019;3(2):158-67.

Arkiv‎: PubMed 30658963

DOI‎: 10.1182/bloodadvances.2018024133

https://www.ncbi.nlm.nih.gov/pubmed/30658963 (åpner nytt vindu)

Idarucizumab for dabigatran reversal. (åpner nytt vindu)

Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI.

Kilde‎: N Engl J Med 2015;373(6):511-20.

Arkiv‎: PubMed 26095746

DOI‎: 10.1056/NEJMoa1502000

https://www.ncbi.nlm.nih.gov/pubmed/26095746 (åpner nytt vindu)

Idarucizumab for dabigatran reversal - full cohort analysis. (åpner nytt vindu)

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

Kilde‎: N Engl J Med 2017;377(5):431-41.

Arkiv‎: PubMed 28693366

DOI‎: 10.1056/NEJMoa1707278

https://www.ncbi.nlm.nih.gov/pubmed/28693366 (åpner nytt vindu)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (åpner nytt vindu)

Reiter RA, Mayr F, Blazicek H, Galehr E, Jilma-Stohlawetz P, Domanovits H, Jilma B

Kilde‎: Blood 2003;102(13):4594-9.

Arkiv‎: PubMed 12920042

DOI‎: 10.1182/blood-2002-11-3566

https://www.ncbi.nlm.nih.gov/pubmed/12920042 (åpner nytt vindu)

Role of agents for reversing the effects of target-specific oral anticoagulants. (åpner nytt vindu)

Riley TR, Gauthier-Lewis ML, Sanchez CK, Douglas JS

Kilde‎: Am J Health Syst Pharm 2017;74(2):54-61.

Arkiv‎: PubMed 27895055

DOI‎: 10.2146/ajhp150810

https://www.ncbi.nlm.nih.gov/pubmed/27895055 (åpner nytt vindu)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (åpner nytt vindu)

Skolnick BE, Shenouda M, Khutoryansky NM, Pusateri AE, Gabriel D, Carr ME.

Kilde‎: Anesth Analg 2011;113(4):703-10.

Arkiv‎: PubMed 21890888

DOI‎: 10.1213/ANE.0b013e318228c690

https://www.ncbi.nlm.nih.gov/pubmed/21890888 (åpner nytt vindu)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (åpner nytt vindu)

Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, Florido R, Hucker W, Mehran R, Messé SR, Pollack CV Jr, Rodriguez F, Sarode R, Siegal D, Wiggins BS

Kilde‎: J Am Coll Cardiol 2017;70(24):3042-67.

Arkiv‎: PubMed 29203195

DOI‎: 10.1016/j.jacc.2017.09.1085

https://www.ncbi.nlm.nih.gov/pubmed/29203195 (åpner nytt vindu)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (åpner nytt vindu)

Woo CH, Patel N, Conell C, Rao VA, Faigeles BS, Patel MC, Pombra J, Akins PT, Axelrod YK, Ge IY, Sheridan WF, Flint AC.

Kilde‎: World Neurosurg 2014;81(1):110-5.

Arkiv‎: PubMed 23220122

DOI‎: 10.1016/j.wneu.2012.12.002

https://www.ncbi.nlm.nih.gov/pubmed/23220122 (åpner nytt vindu)

Reversal of warfarin-induced hemorrhage in the emergency department. (åpner nytt vindu)

Zareh M, Davis A, Henderson S.

Kilde‎: West J Emerg Med 2011;12(4):386-92.

Arkiv‎: PubMed 22224125

DOI‎: 10.5811/westjem.2011.3.2051

https://www.ncbi.nlm.nih.gov/pubmed/22224125 (åpner nytt vindu)

BEHANDLING AV AKUTT KRITISK SYKDOM

Antikoagulasjonsbehandling og reversering

Norsk

Antikoagulasjonsbehandling og reversering

https://assetsnffrgf-a.akamaihd.net/assets/ct/e781f8601f/images/syn_placeholder_sqr.png

Reversal of antithrombotic agents. (åpner nytt vindu)

Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review. (åpner nytt vindu)

Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. (åpner nytt vindu)

Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. (åpner nytt vindu)

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. (åpner nytt vindu)

Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. (åpner nytt vindu)

Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies. (åpner nytt vindu)

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. (åpner nytt vindu)

Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. (åpner nytt vindu)

Emergency reversal of warfarin anticoagulation. (åpner nytt vindu)

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. (åpner nytt vindu)

Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. (åpner nytt vindu)

Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis. (åpner nytt vindu)

Idarucizumab for dabigatran reversal. (åpner nytt vindu)

Idarucizumab for dabigatran reversal - full cohort analysis. (åpner nytt vindu)

Desmopressin antagonizes the in vitro platelet dysfunction induced by GPIIb/IIIa inhibitors and aspirin. (åpner nytt vindu)

Role of agents for reversing the effects of target-specific oral anticoagulants. (åpner nytt vindu)

Reversal of clopidogrel-induced bleeding with rFVIIa in healthy subjects: a randomized, placebo-controlled, double-blind, exploratory study. (åpner nytt vindu)

2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. (åpner nytt vindu)

Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. (åpner nytt vindu)

Reversal of warfarin-induced hemorrhage in the emergency department. (åpner nytt vindu)

Kontakt lokal representant for sykehuskontaktutvalget

Medisinsk informasjonsmateriale

Videoer

Antikoagulasjonsbehandling og reversering

Velg ditt språk

Del